Denosumab increases bone mass but does not reduce fracture risk compared to alendronate
Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysisInt J Clin Pract. 2012 Apr;66(4):399-408. doi: 10.1111/j.1742-1241.2011.02806.x. Epub 2012 Feb 7
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
4 randomised control trials were included in this meta-analysis, to compare the effectiveness of 60mg Denosumab subcutaneously per 6 months (Den) to 70mg Alendronate orally per week (Aln) in the treatment of osteoporosis in postmenopausal women. A total of 1952 women were identified that were followed-up for one year. The primary outcomes were the incidence of clinical fractures and bone mineral d...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE